Riboxin - instructions for use, dose, side effects, contraindications

The tablets covered with a film membrane, from light yellow to yellow-orange color, round, biconcave form. On the cross-section, two layers are visible: the outer layer is yellow, the inner layer is white.

Pharmacotherapeutic group:metabolic

ATX: & nbsp

C.01.E.B Other drugs for the treatment of heart disease

Pharmacodynamics:

Metabolic agent, a precursor of adenosine triphosphate (ATP); has antihypoxic, metabolic and antiarrhythmic effects. Increases the energy balance of the myocardium, improves coronary circulation, prevents the consequences of intraoperative kidney ischemia. It takes a direct part in the exchange of glucose and promotes the activation of metabolism in conditions of hypoxia and in the absence of ATP. Activates the metabolism of pyruvic acid to ensure normal process of tissue respiration, and also promotes the activation of xanthine-dehydrogenase. Stimulates the synthesis of nucleotides, enhances the activity of certain enzymes of the Krebs cycle.Penetrating into cells, it increases energy metabolism, has a positive effect on the metabolic processes in the myocardium, increases the strength of the heart contractions and promotes more complete relaxation of the myocardium in diastole, as a result of which the shock volume of blood increases.

Reduces platelet aggregation, activates the regeneration of tissues (especially myocardium and gastrointestinal mucosa (GI tract)).

Pharmacokinetics:

It is well absorbed in the digestive tract. Metabolised in the liver with the formation of glucuronic acid and its subsequent oxidation. In a small amount is excreted by the kidneys.

Indications:

As part of complex therapy: coronary heart disease, myocardial dystrophy, myocardial infarction, arrythmia with glycoside intoxication; hepatitis, cirrhosis of the liver, fatty liver disease (on the background of alcoholism or the administration of hepatotoxic agents); urocoppororphyria.

Contraindications:

Hypersensitivity to Riboxin and other components of the drug; gout, hyperuricemia; fructose intolerance and glucose / galactose absorption disorder or sugarase / isomaltase deficiency.

Carefully:

Patients with impaired renal function, with diabetes mellitus.

Pregnancy and lactation:

Safety of the drug during pregnancy and in the period of breast

feeding is not established. The use of the drug is contraindicated during pregnancy. For the duration of treatment, breastfeeding should be discontinued.

Dosing and Administration:

Apply inside before eating.

Adults appoint a daily dose of 600-2400 mg. Treatment begins with the application of 200 mg 3-4 times a day. In case of good tolerability, after 2-3 days the dose is increased to 400 mg 3 times a day. Continuing the dose increase every 2-3 days, they switch to taking 400 mg of riboxin at the beginning 4 times a day, and then 6 times a day. The course of treatment is 1-3 months.

With urokopprofirii prescribe 400 mg 4 times a day for 1-3 months.

Side effects:

Hyperuricemia and exacerbation of gout (with prolonged use of high doses), allergic reactions (urticaria, skin itching, skin hyperemia).

Overdose:

There were no cases of drug overdose.

Interaction:

Immunosuppressants (azathioprine, antilympholine, ciclosporin, thymodepressin, etc.) with simultaneous administration reduce the effectiveness of riboxin.

Special instructions:

One tablet contains 0.00644 units of bread (XE).

When using the drug in patients with impaired renal function, it is recommended to control the level of uric acid and urea in the blood.

Effect on the ability to drive transp. cf. and fur:

The drug does not affect the ability of the patient to manage motor vehicle or other machinery.

Form release / dosage:

Tablets, film-coated, 200 mg.

Packaging:

10 tablets per contour cell pack.

For 5 contour mesh packages together with the instruction for use are placed in a pack of cardboard.

Storage conditions:

Keep in dry the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

After expiration date the drug should not be used.

Terms of leave from pharmacies:On prescription

Registration number:LS-001829

Date of registration:06.09.2011

The owner of the registration certificate:IRBITSK HFZ, OJSC IRBITSK HFZ, OJSC Russia

Manufacturer: & nbsp

IRBITSK HFZ, OJSC Russia

Information update date: & nbsp22.10.2015

Illustrated instructions

Instructions

Riboxin (Riboxin)